Panel Discussion and Forum on Lecanemab

Drs. Adam Boxer, Gil Rabinovici and Winston Chiong
Memory and Aging Center
University of California, San Francisco

Objectives

• To understand the FDA approval process with lecanemab
• To understand different viewpoints regarding lecanemab efficacy
• To understand issues regarding lecanemab safety
• To understand issues regarding equity and implementation of lecanemab

Disclosures

• Planners: Bruce L. Miller, MD; Howard J. Rosen, MD; Andrew Breithaupt, MD; and Eleanor O’Brien have stated they have no relationships to disclose.
• Speakers: Adam Boxer, MD, PhD, has disclosed the following relationships: Alector, Arkuda, Arvinas, AZTherapies, TrueBinding, AGTC, Alzprotect, Aviado, Boehringer Ingelheim, Denali, GSK, Life Edit, Humana, Merck, Modalis, Oligomerix, Oscotec, Roche, Transposon, Wave, Biogen, Eisai, Regeneron, Denali. Gil Rabinovici, MD, has disclosed the following relationships: Eli Lilly, Roche, Genentech, Alector, GE Healthcare, Merck, Johnson & Johnson. Winston Chiong, MD, PhD, has stated he has no relationships to disclose.

Accreditation: The University of California, San Francisco (UCSF) School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation: UCSF designates this live activity for a maximum of 22 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Credit is inclusive of all Memory and Aging Center Grand Rounds sessions offered from January 1, 2023, through December 31, 2023. (1 credit per each 1-hour grand rounds session throughout the year).

Questions? Email Andrew Breithaupt, MD, at Andrew.Breithaupt@ucsf.edu.

Attendees must register for this event. Grand Rounds presentations are for educational purposes and intended for a professional audience with a terminal degree. This activity is not commercially supported.